Anti-inflammatory and PPAR transactivational properties of flavonoids from the roots of Sophora flavescens

Phytotherapy Research

Volumn 27, Issue 9, 2013, Pages 1300-1307

  Quang, Tran Hong ^a,b   Ngan, Nguyen Thi Thanh ^a   Minh, Chau Van ^b   Kiem, Phan Van ^b   Tai, Bui Huu ^a,b   Nhiem, Nguyen Xuan ^a,b   Thao, Nguyen Phuong ^a,b   Luyen, Bui Thi Thuy ^a   Yang, Seo Young ^a   Kim, Young Ho ^a  

^a Chungnam National University   (South Korea)

^b GRADUATE UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Viet Nam)

Author keywords

Flavonoid, NF B luciferase assay; Leguminosae; PPRE luciferase assay; RT PCR; Sophora flavescens

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; BEZAFIBRATE; CIPROFIBRATE; CYCLOOXYGENASE 2; FLAVONOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SOPHORA FLAVESCENS EXTRACT; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLOOXGENASE 2 GENE; DNA RESPONSIVE ELEMENT; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; INDUCIBLE NITRIC OXIDE SYNTHASE GENE; NONHUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR TRANSACTIVATIONAL ACTIVITY; PEROXISOME PROLIFERATOR RESPONSE ELEMENT; PLANT ROOT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOPHORA FLAVESCENS; TRANSCRIPTION REGULATION; UPREGULATION;

FLAVONOID, NF-ΚB-LUCIFERASE ASSAY; LEGUMINOSAE; PPRE-LUCIFERASE ASSAY; RT-PCR; SOPHORA FLAVESCENS;

ANTI-INFLAMMATORY AGENTS; CYCLOOXYGENASE 2; FLAVONOIDS; HEP G2 CELLS; HUMANS; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PLANT EXTRACTS; PLANT ROOTS; SOPHORA; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874902650     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4871     Document Type: Article

References (54)

1. Baldwin ASJ,. 1996. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683.
2. Baldwin ASJ,. 2001. Series introduction: the transcription factor NF-kappa B and human disease. J Clin Invest 107: 3-6.
3. Balint BL, Nagy L,. 2006. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. Endocr Metab Immune Disord Drug Targets 6: 33-43.
4. Barak Y, Liao D, He W, et al,. 2002. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 99: 303-308.
5. Barish GD, Narkar VA, Evans RM,. 2006. PPARdelta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590-597.
6. Berger J, Moller DE,. 2002. The Mechanisms of action of PPARs. Annu Rev Med 53: 409-435.
7. Bonizzi G, Karin M,. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288.
8. Chang HM, But PPH,. 1986. Pharmacology and Application of Chinese Materia Medica. World Scientific Publishers: Philaldephia; 736.
9. Cheon BS, Kim YH, Son KS, Chang HW, Kang SS, Kim HP,. 2000. Effects of prenylated flavonoids and biflavonoids on lipopolysaccharide-induced nitric oxide production from the mouse macrophage cell line RAW 264.7. Planta Med 66: 596-600.
10. Evans RM,. 1988. The steroid and thyroid hormone receptor superfamily. Science 240: 889-895.
11. Gervois P, Kleemann R, Pilon A, et al,. 2004. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem 279: 16,154-16,160.
12. Ghosh S, May MJ, Kopp EB,. 1998. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260.
13. Gilmore TD,. 2006. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25: 6680-6684.
14. Gross B, Staels B,. 2007. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best. Pract. Res. Cl. En. 21: 687-710.
15. Haluzik MM, Haluzik M,. 2006. PPAR-alpha and insulin sensitivity. Physiol Res 55: 115-122.
16. Hoffmann A, Baltimore D,. 2006. Circuitry of nuclear factor kappaB signaling. Immunol Rev 210: 171-186.
17. Hsu H, Shu HB, Pan MG, Goeddel DV,. 1996. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84: 299-308.
18. Kang SS, Kim JS, Son KH, Chang HW, Kim HP,. 2000a. A new prenylated flavanone from the roots of Sophora flavescens. Fitoterapia 71: 511-515.
19. Kang TH, Jeong SJ, Ko WG, et al,. 2000b. Cytotoxic lavandulyl flavanones from Sophora flavescens. J Nat Prod 63: 680-681.
20. Kaplan F, Al-Majali K, Betteridge DJ,. 2001. PPARS, insulin resistance and type 2 diabetes. J Cardiovasc Risk 8: 211-217.
21. Kersten S, Desvergne B, Wahli W,. 2000. Roles of PPARs in health and disease. Nature 405: 421-424.
22. Kim DW, Chi YS, Son KH, et al,. 2002. Effects of sophoraflavanone G, a prenylated flavonoid from Sophora flavescens, on cyclooxygenase-2 and in vivo inflammatory response. Arch Pharm Res 25: 329-35.
23. Kim HK, Cheon BS, Kim YH, Kim SY, Kim HP,. 1999. Effects of naturally occurring flavonoids on nitric oxide production in the macrophage cell line RAW 264.7 and their structure-activity relationships. Biochem Pharmacol 58: 759-765.
24. Kim KK, Park KS, Song SB, Kim KE,. 2010. Up regulation of GW112 Gene by NF kappaB promotes an antiapoptotic property in gastric cancer cells. Mol Carcinog 49: 259-270.
25. Ko WG, Kang TH, Kim NY, et al,. 2000. Lavandulylflavonoids: a new class of in vitro apoptogenic agents from Sophora flavescens. Toxicol In Vitro 14: 429-433.
26. Kuroda M, Mimaki Y, Honda S, Tanaka H, Yokota S, Mae T,. 2010. Phenolics from Glycyrrhiza glabra roots and their PPAR-gamma ligand-binding activity. Bioorg Med Chem 18: 962-970.
27. Kuroyanagi M, Arakawa T, Hirayama Y, Hayashi T,. 1999. Antibacterial and antiandrogen flavonoids from Sophora flavescens. J Nat Prod 62: 1595-1599.
28. Lazar MA,. 2005. PPAR gamma, 10 years later. Biochimie 87: 9-13.
29. Lee CH, Olson P, Hevener A, et al,. 2006. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 103: 3444-3449.
30. Lehrke M, Lazar MA,. 2005. The many faces of PPARgamma. Cell 123: 993-999.
31. Li Q, Verma IM,. 2002. NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725-734.
32. Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF, Lin JK,. 1999. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20: 1945-1952.
33. Mandard S, Muller M, Kersten S,. 2004. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61: 393-416.
34. Moller DE,. 2001. New drug targets for type II diabetes and the metabolic syndrome. Nature 414: 821-827.
35. Moras D, Gronemeyer H,. 1998. The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 10: 384-391.
36. Murphy GJ, Holder JC,. 2000. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21: 469-474.
37. Ngan NT, Quang TH, Tai BH, Song SB, Lee D, Kim YH,. 2012. Anti-inflammatory and PPAR transactivational effects of components from the stem bark of Ginkgo biloba. J Agric Food Chem 60: 2815-2824.
38. Pahl HL,. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866.
39. Pande V, Ramos MJ,. 2005. NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. Curr Med Chem 12: 357-74.
40. Peters JM, Lee SS, Li W, et al,. 2000. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 20: 5119-5128.
41. Phelps CB, Sengchanthalangsy LL, Huxford T, Ghosh G,. 2000. Mechanism of IkappaBalpha binding to NF-kappaB dimers. J Biol Chem 275: 29,840-29,846.
42. Quang TH, Ngan NT, Minh CV, et al,. 2011. Anti-inflammatory triterpenoid saponins from the stem bark of Kalopanax pictus. J Nat Prod 74: 1908-1915.
43. Quang TH, Ngan NT, Minh CV, et al,. 2012a. Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii. Bioorg Med Chem Lett 22: 2527-2533.
44. Quang TH, Ngan NTT, Minh CV, et al,. 2012b. alpha-Glucosidase Inhibitors from the Roots of Sophora flavescens. Bull. Korean Chem. Soc. 33: 1791-1793.
45. Raingeaud J, Gupta S, Rogers JS, et al,. 1995. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270: 7420-7426.
46. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA,. 1998. Interdomain communication regulating ligand binding by PPAR-gamma. Nature 396: 377-380.
47. Shearer BG, Billin AN,. 2007. The next generation of PPAR drugs: Do we have the tools to find them? BBA-Mol. Cell. Biol. L. 1771: 1082-1093.
48. Shin HJ, Kim HJ, Kwak JH, et al,. 2002. A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett 12: 2313-2316.
49. Smith CA, Farrah T, Goodwin RG,. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76: 959-962.
50. Staels B, Koenig W, Habib A, et al,. 1998. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793.
51. Straus DS, Glass CK,. 2007. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28: 551-558.
52. Tian B, Nowak DE, Brasier AR,. 2005. A TNF-induced gene expression program under oscillatory NF-kappaB control. BMC Genomics 6: 137.
53. Verges B,. 2004. Clinical interest of PPARs ligands. Diabetes Metab 30: 7-12.
54. Woo ER, Kwak JH, Kim HJ, Park H,. 1998. A new prenylated flavonol from the roots of Sophora flavescens. J Nat Prod 61: 1552-1554